About Us
Fresenius Kabi Global at a glance
Our product portfolio comprises of a comprehensive range of IV generic medicines, infusion therapies and clinical nutrition products as well as the devices for administering these products. In the field of biosimilars, we focus on autoimmune diseases and oncology. In 2019, the first biosimilar product by Fresenius Kabi was launched. Within transfusion medicine and cell therapies, Fresenius Kabi offers products for collection of blood components and extracorporeal therapies.
Fresenius Kabi employs around 40,500 people worldwide.
With our corporate philosophy of "caring for life", we are committed to putting essential medicines and technologies in the hands of people who help patients and finding the best answers to the challenges they face.
In 2020, the company reported sales of around €7.0 billion. Fresenius Kabi AG is a wholly owned subsidiary of the Fresenius SE & Co. KGaA healthcare group.
Key Figures
| € in millions | 2020 | 2019 |
| Sales | 6,976 | 6,919 |
| EBITDA1 | 1,490 | 1,573 |
| EBIT1 | 1,095 | 1,205 |
| Net Income 1,2 | 730 | 797 |
| Employees (Dec 31) | 40,519 | 39,627 |
1 Before special terms
2 Net income attributes to shareholders of Fresenius SE & Co. KGaA
